USPTO Examiner RAMACHANDRAN UMAMAHESWARI - Art Unit 1627

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19270230Tricyclic Fused Heterocyclic PDE3/4 Dual Inhibitor and Use ThereofJuly 2025December 2025Allow510YesNo
19208335METHODS AND COMPOSITIONS FOR TREATING EDEMA REFRACTORY TO ORAL DIURETICSMay 2025July 2025Allow200YesNo
19097314COMPOSITIONS FOR THE TREATMENT OF HYPERTENSIONApril 2025August 2025Allow500YesNo
19073585COMPOSITIONS FOR THE TREATMENT OF HYPERTENSIONMarch 2025August 2025Allow510YesNo
19000003INDOXACARB SUSPENSION CONCENTRATE FORMULATIONSDecember 2024September 2025Allow910YesNo
18955937METHOD OF INHIBITING TAU PHOSPHORYLATIONNovember 2024February 2026Allow1520YesNo
18955938METHOD OF INHIBITING TAU PHOSPHORYLATIONNovember 2024February 2026Allow1510YesNo
18926907METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMENOctober 2024February 2025Allow310YesNo
18916471METHODS AND COMPOSITIONS FOR TREATING EDEMA REFRACTORY TO ORAL DIURETICSOctober 2024April 2025Allow610YesNo
18743946(E)-1-(2-(4-SUBSTITUTEDPHENYL)-2-OXOETHYL)-4-((HYDROXYIMINO)METHYL)PYRIDINIUM BROMIDES AS ANTITUBERCULAR AGENTSJune 2024September 2024Allow300NoNo
18676249NICORANDIL DERIVATIVESMay 2024June 2025Allow1310YesNo
18668653STABLE PHARMACEUTICAL COMPOSITION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG DERIVATIVEMay 2024June 2025Allow1310YesNo
18642051In Vitro and Xenograft Anti-Tumor Activity of a Halogenated-Xanthene Against Refractory Pediatric Solid TumorsApril 2024May 2025Allow1310YesNo
18638787METHOD FOR CONTROLLING RUSTApril 2024July 2025Abandon1510NoNo
18696857VANIN-1 INHIBITORMarch 2024June 2024Allow200YesNo
18620393COMPOSITIONS CONTAINING PARAXANTHINE AND BETA-HYDROXYBUTYRATE OR PRECURSOR FOR INCREASING NEUROLOGICAL AND PHYSIOLOGICAL PERFORMANCEMarch 2024July 2024Allow300YesNo
18601923NOVEL COMPOUNDS AND METHODSMarch 2024October 2025Allow1910YesNo
18595919USE OF THYROID BETA-AGONISTSMarch 2024July 2025Allow1611NoNo
18587006METHODS OF TREATING OBESITY USING ANTIOXIDANT INFLAMMATION MODULATORSFebruary 2024July 2025Abandon1601NoNo
184232014-[4,4-BIS(4-CHLOROPHENYL)-2,5-DIOXOIMIDAZOLIDIN-1-YL]BUTANOIC ACID AS AN ANTIMICROBIAL COMPOUNDJanuary 2024August 2024Allow701YesNo
18393556METHODS FOR INHIBITING FASCINDecember 2023April 2025Allow1601NoNo
18540628TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORSDecember 2023March 2026Abandon2720YesNo
18520091METHOD OF TREATING A PERSON AFFLICTED WITH A RESPIRATORY CONDITION AND PHARMACEUTICAL FORMULATION INCLUDING DAPSONENovember 2023April 2025Allow1710YesNo
18508830BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONSNovember 2023April 2025Allow1710YesNo
18389167EMULSION FORMULATIONSNovember 2023March 2025Allow1610YesNo
18501814IMMEDIATE AND CONTROLLED RELEASE APPETITE SUPPRESSANT COMPOSITIONS FOR WEIGHT LOSSNovember 2023February 2025Allow1511YesNo
18386017(E)-1-(2-(4-SUBSTITUTEDPHENYL)-2-OXOETHYL)-4-((HYDROXYIMINO)METHYL)PYRIDINIUM BROMIDES AS ANTITUBERCULAR AGENTSNovember 2023October 2024Abandon1211NoNo
18494441COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING DISEASES OR DISORDERS ASSOCIATED WITH PROTEIN MISFOLDINGOctober 2023June 2025Abandon1911NoNo
18491319METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMENOctober 2023June 2024Allow810NoNo
18491301METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMENOctober 2023May 2024Allow710YesNo
18491311METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMENOctober 2023June 2024Allow810YesNo
18491291METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMENOctober 2023April 2024Allow610NoNo
18484564LIQUID NIMODIPINE COMPOSITIONSOctober 2023April 2025Allow1810NoNo
18483780THERAPEUTIC USES OF 1-[2-(2,4-DIMETHYL-PHENYLSULFANYL)PHENYL]PIPERAZINEOctober 2023April 2025Abandon1810NoNo
18244168NON-AQUEOUS LIQUID NIMODIPINE COMPOSITIONSSeptember 2023September 2024Allow1220YesNo
18446268COMPOSITIONS FOR THE TREATMENT OF HYPERTENSIONAugust 2023February 2025Allow1811YesNo
18356182COMPOSITIONS AND METHODS FOR AMELIORATING HELICOBACTERACEAE INFECTIONSJuly 2023February 2026Allow3101YesNo
18355802METHOD OF VIRAL INHIBITIONJuly 2023August 2024Allow1300YesNo
18222681METHOD OF TREATMENT OF CNS DISORDERSJuly 2023November 2025Allow2820YesNo
18218372Levodopa Fatty Acid Derivatives, Formulations Thereof, and Their Uses for the Treatment of Parkinson's DiseaseJuly 2023March 2024Allow911YesNo
18207893INTELLIGENT DELIVERY OF INGESTED AND ABSORBED MOLECULESJune 2023March 2025Abandon2211NoNo
18331688COMPOSITIONS AND METHODS FOR TREATING OCULAR DISORDERSJune 2023May 2025Allow2310YesNo
18323075METHOD OF INHIBITING TAU PHOSPHORYLATIONMay 2023July 2025Abandon2610NoNo
18319220APPLICATION OF PYRROLE-2-CARBOXALDEHYDE IN CONTROLLING PLANT ROOT-KNOT NEMATODESMay 2023June 2024Abandon1311NoNo
18312466STABLE PHARMACEUTICAL COMPOSITION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG DERIVATIVEMay 2023December 2023Allow710YesNo
18248644COMPOUNDS FOR TREATMENT OF HEMOLYSIS-AND INFLAMMASOME-ASSOCIATED DISEASESApril 2023March 2026Allow3510YesNo
18182125COMPOSITIONS CONTAINING PARAXANTHINE AND BETA-HYDROXYBUTYRATE OR PRECURSOR FOR INCREASING NEUROLOGICAL AND PHYSIOLOGICAL PERFORMANCEMarch 2023March 2024Allow1230YesNo
18118209METHODS OF TREATING MULTIPLE SCLEROSISMarch 2023September 2025Abandon3130YesYes
18180064USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)March 2023September 2024Abandon1821NoNo
18024948ANTICOCCIDIAL COMPOSITION COMPRISING STILBENE-BASED COMPOUND, AND USE THEREOFMarch 2023January 2026Allow3510YesNo
18176816METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMENMarch 2023July 2023Allow410YesNo
18176860METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMENMarch 2023July 2023Allow410YesNo
18176855METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMENMarch 2023July 2023Allow500YesNo
18175142FOOD SUPPLEMENT AND COMPOSITION COMPRISING CHOLINE BUTYRATE SALT AND/OR BUTYRYLCHOLINEFebruary 2023December 2024Allow2220YesNo
18175123FOOD SUPPLEMENT AND COMPOSITION COMPRISING CHOLINE BUTYRATE SALT AND/OR BUTYRYLCHOLINEFebruary 2023March 2025Abandon2420NoNo
18114305METHOD AND COMPOSITIONS FOR TREATMENT AND PREVENTION OF BROAD SPECTRUM VIRUS AILMENTS COMPRISING A CALCIUM CHANNEL BLOCKER OR A CALMODULIN BLOCKERFebruary 2023December 2024Abandon2201NoNo
18171254USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)February 2023May 2025Abandon2731NoNo
18107741USE OF SELECTIVE GABA A ALPHA 5 NEGATIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONSFebruary 2023September 2025Abandon3121YesNo
18040035FORMULATIONSJanuary 2023December 2025Allow3410YesNo
18007153COCRYSTAL COMPRISING CAMOSTAT AND NICLOSAMIDE, PHARMACEUTICAL COMPOSITION COMPRISING SAME AND PREPARATION METHOD THEREFORJanuary 2023November 2025Allow3410YesNo
18102136MODULATION OF SOLUBILITY, STABILITY, ABSORPTION, METABOLISM, AND PHARMACOKINETIC PROFILE OF LIPOPHILIC DRUGS BY STEROLSJanuary 2023January 2025Allow2410YesNo
18152399SLEEP DISORDER TREATMENT AND PREVENTIONJanuary 2023August 2024Allow1910NoNo
18150993METHODS AND COMPOSITIONS INVOLVING BUCINDOLOL FOR THE TREATMENT OF ATRIAL FIBRILLATIONJanuary 2023August 2025Allow3120YesNo
18148682METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMENDecember 2022June 2023Allow610YesNo
18003947SALT OF DEMETHYL TRAMADOL AND USE THEREOFDecember 2022February 2026Abandon3810NoNo
18090547SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIBDecember 2022October 2023Allow911YesNo
18088756METHODS AND AGENTS THAT ENHANCE MYOGENIC PROGENITOR CELL ENGRAFTMENTDecember 2022May 2024Allow1701YesNo
18068403TREATMENT OF HERPES ZOSTER WITH TOPICAL TETRACAINEDecember 2022July 2024Allow1920YesNo
18081390COMPOSITION COMPRISING TETRACYCLIC COMPOUNDDecember 2022July 2024Abandon1901NoNo
18062911METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDERDecember 2022August 2024Abandon2111NoNo
18076044METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTORDecember 2022July 2024Abandon2010NoNo
18075634METHOD OF USING SUBSTRATES OF AKR1Bl/AKR1B10 AS ANTI-CANCER DRUGSDecember 2022September 2025Abandon3321NoNo
18007732METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONSDecember 2022January 2026Allow3711YesNo
17993216Treatment Of AdipocytesNovember 2022April 2024Allow1710YesNo
17927240ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE AND FOR MAKING SAMENovember 2022February 2026Abandon3910NoNo
17998819SYNERGISTIC FUNGICIDAL INTERACTIONS OF A PICOLINAMIDE FUNGICIDE WITH OTHER FUNGICIDES AGAINST ASIAN SOYBEAN RUSTNovember 2022February 2026Abandon3910NoNo
17998731ALLEVIATION OF LIVER INJURY BY ACTIVATING THE SIGNALING PATHWAY MEDIATED BY FARNESOID X RECEPTORNovember 2022February 2026Abandon3910NoNo
17925102PYRROLIDINE COMPOUND AND USE THEREOFNovember 2022November 2025Allow3610YesNo
17924420COMPOUND AND COMPOSITION FOR INDUCING NEUROPROTECTIONNovember 2022December 2025Allow3810YesNo
17923641DOSAGE REGIMEN OF AMLODIPINENovember 2022February 2026Allow3910YesNo
17974027LIQUID NIMODIPINE COMPOSITIONSOctober 2022July 2023Allow810YesNo
17974032LIQUID NIMODIPINE COMPOSITIONSOctober 2022July 2023Allow810NoNo
17920946COMPOSITIONS AND METHODS FOR TREATING LUNG INJURYOctober 2022March 2026Allow4111YesNo
17920611Use of Salmeterol as an Anti-Coronaviral AgentOctober 2022April 2025Allow3000YesNo
17920502Methods and Materials for Treatment of FibrosisOctober 2022March 2026Allow4011YesNo
17996554COMPOSITION AND METHODS FOR TREATING RESPIRATORY DISEASESOctober 2022March 2026Allow4111YesNo
17965150USE OF METABOLIC REGULATORS FOR THE TREATMENT OF COVID-19October 2022January 2026Abandon3901NoNo
18046492DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONISTOctober 2022September 2024Allow2310YesNo
17955337METHOD OF TREATING A PERSON AFFLICTED WITH COVID-19 AND PHARMACEUTICAL FORMULATION INCLUDING DAPSONESeptember 2022July 2023Allow1010YesNo
17907470KETONE ESTER AS A THERAPEUTIC TREATMENT OF COVID -19 AND RELATED VIRAL INFECTIONSSeptember 2022May 2025Allow3200YesNo
17914230DISINFECTION SOLUTION WITH TWO-PART FORMULATIONSeptember 2022January 2026Abandon4010NoNo
17947789COMPOSITIONS AND METHODS FOR TREATING AN INFECTIONSeptember 2022February 2024Allow1710YesNo
17932982COMPOSITIONS FOR THE TREATMENT OF HYPERTENSIONSeptember 2022June 2024Allow2110YesNo
17911231METHODS OF TREATING MULTIPLE SCLEROSISSeptember 2022August 2025Abandon3520NoNo
17911402METHODS OF CONTROLLING OR PREVENTING INFESTATION OF PLANTS BY THE PHYTOPATHOGENIC MICROORGANISM CORYNESPORA CASSIICOLASeptember 2022December 2025Abandon3910NoNo
17903372THERAPEUTIC USE OF COMPOUNDSSeptember 2022May 2024Allow2011YesNo
17901896HIGH CONCENTRATION MEDICANT SOLUTIONS FOR TREATING NEUROLOGICAL DISORDERSSeptember 2022August 2024Abandon2310NoNo
17908686ISOPAUCIFLORAL F PHOSPHATE COMPOUND AND PHARMACEUTICAL USE THEREOFSeptember 2022May 2025Allow3200YesNo
17908516COMPOSITIONS AND METHODS FOR INHIBITING A FUNGAL PATHOGENAugust 2022January 2026Abandon4101NoNo
17898196ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORSAugust 2022May 2024Abandon2001NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RAMACHANDRAN, UMAMAHESWARI.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
26
Examiner Affirmed
24
(92.3%)
Examiner Reversed
2
(7.7%)
Reversal Percentile
22.3%
Lower than average

What This Means

With a 7.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
120
Allowed After Appeal Filing
28
(23.3%)
Not Allowed After Appeal Filing
92
(76.7%)
Filing Benefit Percentile
31.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 23.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner RAMACHANDRAN, UMAMAHESWARI - Prosecution Strategy Guide

Executive Summary

Examiner RAMACHANDRAN, UMAMAHESWARI works in Art Unit 1627 and has examined 1,109 patent applications in our dataset. With an allowance rate of 51.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner RAMACHANDRAN, UMAMAHESWARI's allowance rate of 51.0% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by RAMACHANDRAN, UMAMAHESWARI receive 1.85 office actions before reaching final disposition. This places the examiner in the 43% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by RAMACHANDRAN, UMAMAHESWARI is 33 months. This places the examiner in the 45% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +55.2% benefit to allowance rate for applications examined by RAMACHANDRAN, UMAMAHESWARI. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 20.4% of applications are subsequently allowed. This success rate is in the 22% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 33.5% of cases where such amendments are filed. This entry rate is in the 50% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 66.2% of appeals filed. This is in the 47% percentile among all examiners. Of these withdrawals, 62.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 57.1% are granted (fully or in part). This grant rate is in the 59% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.5% of allowed cases (in the 71% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.7% of allowed cases (in the 57% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.